Sugi Predict

Sugi Predict / Targets / PAK5

PAK5

Serine/threonine-protein kinase PAK 5 · Q9P286 · PAK5 on Sugi Atlas →

970 patent compounds predicted against PAK5, 830 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1614473 SCHEMBL1614473 0.42 2/20
SCHEMBL1614224 SCHEMBL1614224 0.41 2/20
SCHEMBL1611663 SCHEMBL1611663 0.41 2/20
SCHEMBL899872 SCHEMBL899872 1.00 1/20
SCHEMBL900582 SCHEMBL900582 1.00 1/20
SCHEMBL1352147 SCHEMBL1352147 1.00 1/20
SCHEMBL1353814 SCHEMBL1353814 1.00 1/20
SCHEMBL1613241 SCHEMBL1613241 1.00 1/20
SCHEMBL11971116 SCHEMBL11971116 1.00 1/20
SCHEMBL13624896 SCHEMBL13624896 1.00 1/20
SCHEMBL14977351 SCHEMBL14977351 1.00 1/20
SCHEMBL15389179 SCHEMBL15389179 1.00 1/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL900878) 0.98 1/20
SCHEMBL1353462 SCHEMBL1353462 0.97 1/20
SCHEMBL1353566 SCHEMBL1353566 0.97 1/20
SCHEMBL1353568 SCHEMBL1353568 0.97 1/20
Acetic Acid Acetic Acid (SCHEMBL15255188) 0.93 1/20
SCHEMBL2627083 SCHEMBL2627083 0.85 1/20
SCHEMBL1355346 SCHEMBL1355346 0.84 1/20
SCHEMBL16195108 SCHEMBL16195108 0.84 1/20

Clinical trials — most relevant to PAK5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma PHASE1/PHASE2COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer PHASE1/PHASE2COMPLETED
A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer PHASE2COMPLETED
Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals PHASE1/PHASE2COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety PHASE2COMPLETED
Selective Treatment According to Molecular Subtype of Prostate Cancer PHASE2UNKNOWN
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
Pembrolizumab (MK-3475) in MM Patients With Residual Disease PHASE2COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia PHASE1COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers PHASE1COMPLETED
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients nanCOMPLETED
Rostock International Parkinson's Disease Study (ROPAD) nanCOMPLETED
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder. nanCOMPLETED
Investigating the Genetic Basis of Pseudoexfoliation Syndrome, Angle-closure Glaucoma and Primary Open-angle Glaucoma nanRECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease nanRECRUITING
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia nanRECRUITING
Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis nanNOT_YET_RECRUITING
Expression of EPK in Recurrent Miscarriage nanCOMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PAK5 binder may also engage these)

ProteinNameSimilarity
Q8C015 — 1.000 Q8C015 →
D4A280 — 1.000 D4A280 →
A7MBB4 — 0.999 A7MBB4 →
MAP4K4 Mitogen-activated protein kinase kinase kinase kinase 4 0.998 landscape →
Q5R8Z4 — 0.997 Q5R8Z4 →
TNIK TRAF2 and NCK-interacting protein kinase 0.997 landscape →
Q9JKV2 — 0.996 Q9JKV2 →
Q9H329 — 0.996 Q9H329 →
Q3UTQ8 — 0.996 Q3UTQ8 →
Q9DDT2 — 0.995 Q9DDT2 →
P83038 — 0.995 P83038 →
H2L099 — 0.995 H2L099 →
Q6P4S6 — 0.995 Q6P4S6 →
O14490 — 0.995 O14490 →
SNRK SNF-related serine/threonine-protein kinase 0.994 landscape →
Q5HZJ0 — 0.994 Q5HZJ0 →
Q9JLM8 — 0.994 Q9JLM8 →
Q4JIM5 — 0.994 Q4JIM5 →
Q148W8 — 0.994 Q148W8 →
PAX3 Paired box protein Pax-3 (HuP2) 0.994 landscape →
KAT6B Histone acetyltransferase KAT6B 0.994 landscape →
Q3ULB5 — 0.993 Q3ULB5 →
Q9UQ26 — 0.993 Q9UQ26 →
SIK3 Serine/threonine-protein kinase SIK3 0.993 landscape →
A7SNN5 — 0.993 A7SNN5 →
Q05512 — 0.993 Q05512 →
Q9D415 — 0.993 Q9D415 →
Q7RZD3 — 0.993 Q7RZD3 →
CCNT2 Cyclin-T2 0.993 landscape →
Q80VW5 — 0.993 Q80VW5 →